Clinical and pathological characteristics of peripheral T‐cell lymphomas in a Spanish population: a retrospective study

Abstract

We investigated the clinicopathological features and prognostic factors of patients with peripheral T-cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the International Prognostic Index and the Intergruppo Italiano Linfomi system, treatments, and clinical outcomes were examined. A sizeable proportion of 175 patients had a history of immune-related disorders (autoimmune 16%, viral infections 17%, chemo/radiotherapy-treated carcinomas 19%). The median progression-free survival (PFS) and overall survival (OS) were 7Á9 and 15Á8 months, respectively. Prognostic indices influenced PFS and OS, with a higher number of adverse factors resulting in shorter survival (P < 0Á001). Complete response (CR) to treatment was associated with better PFS (62Á6 vs. 4 months; P < 0Á001) and longer OS (67Á0 vs. 7Á3 months; P < 0Á001) compared to no CR. CD30 was expressed across all subtypes; >15% of cells were positive in anaplastic lymphoma kinase-positive and-negative anaplastic large-cell lymphoma and extranodal natural killer PTCL groups. We observed PTCL distribution across subtypes based on haematopathological re-evaluation. Poor prognosis, effect of specific prognostic indices, relevance of histopathological subclassification, and response level to first-line treatment on outcomes were confirmed. Immune disorders amongst patients require further examination involving genetic studies and identification of associated immunosuppressive factors.

The clinical features, treatment, and prognostic factors for peripheral T‐cell lymphomas: A single‐institution analysis of 240 Chinese patients

“…In agreement with previous studies, 19,21 our study found that achieving CR after frontline chemotherapy was significantly associated with more favorable outcomes. The COMPLETE study also confirmed that patients in CR1 had significantly longer OS and PFS and highlighted the potential significance of CR1 status for ASCT.…”

“…The median age at diagnosis across major subtypes was relatively lower in our study than that previously reported in western countries, 19–21 while similar to previous Chinese series 22,23 . Other clinical features of our patients were in keeping with other studies 19–21 . Consistent with other studies, AITL usually presented with aggressive clinical features, including advanced stage, B symptoms, elevated LDH and β2M, and higher IPI or PIT scores 6,21,24,25 .…”

“…The median age at diagnosis across major subtypes was relatively lower in our study than that previously reported in western countries, 19–21 while similar to previous Chinese series 22,23 . Other clinical features of our patients were in keeping with other studies 19–21 .…”

“…Other clinical features of our patients were in keeping with other studies 19–21 . Consistent with other studies, AITL usually presented with aggressive clinical features, including advanced stage, B symptoms, elevated LDH and β2M, and higher IPI or PIT scores 6,21,24,25 . In contrast, ALK+ALCL typically exhibited low‐risk features, with a majority of patients classified as low or low/intermediate risk groups defined by the IPI or PIT 26,27 …”

“…[19][20][21] Consistent with other studies, AITL usually presented with aggressive clinical features, including advanced stage, B symptoms, elevated LDH and β2M, and higher IPI or PIT scores. 6,21,24,25 In contrast, ALK+ALCL typically exhibited low-risk features, with a majority of patients classified as low or low/intermediate risk groups defined by the IPI or PIT. 26,27 The 5-year PFS and OS of all PTCL patients in our study were 30.4% and 48.8%, respectively, which were numerically lower compared with Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; ALK+ALCL, anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma; ALK-ALCL, anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma; ASCT, autologous stem cell transplantation; BM, bone marrow; Chemo, chemotherapy; CI, confidence interval; CR, complete response; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; LMR, the lymphocyte to monocyte ratio; ND, not done; NLR, the neutrophil to lymphocyte ratio; PS, performance status; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; β2M, β2-microglobulin.…”